Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage

Hypertension

Volumn 40, Issue 6, 2002, Pages 840-846

  Muller, Dominik N ^a,b   Mullally, Alexander ^a   Dechend, Ralf ^a   Park, Joon Keun ^c   Fiebeler, Anette ^a   Pilz, Bernhard ^a   Löffler, Bernd Michael ^d   Blum Kaelin, Denise ^d   Masur, Stefan ^d   Dehmlow, Henrietta ^d   Aebi, Johannes D ^d   Haller, Hermann ^c   Luft, Friedrich C ^a,b,e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Angiotensin II; Enzymes; Fibrosis; Hypertrophy

Indexed keywords

ANGIOTENSIN; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR; RENIN; RO 06877629; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; EUTHANASIA; HEART INJURY; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; AORTA; ASPARTIC ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ENDOTHELIN-1; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 2; FIBRONECTINS; HEART DISEASES; HEART VENTRICLES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; METALLOENDOPEPTIDASES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RENIN; RNA, MESSENGER;

EID: 0036899332     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000039748.88581.A0     Document Type: Article

References (25)

1. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol. 2001;280:R1388-R1392.
2. Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft FC. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension. 2000;35:587-594.
3. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Loffler BM, Ganten D, Schneider W, Haller H, Luft FC. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 2000;36: 282-290.
4. Bohlender J, Gerbaulet S, Kramer J, Gross M, Kirchengast M, Dietz R. Synergistic effects of AT(l) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension. 2000; 35:992-997.
5. Kedzierski RM, Yanagisawa M. Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41: 851-876.
6. Bur D, Dale GE, Oefner C. A three-dimensional model of endothelinconverting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP). Protein Eng. 2001;14:337-341.
7. Nambi P, Clozel M, Feuerstein G. Endothelin and heart failure. Heart Fail Rev. 2001;6:335-340.
8. Aebi J, Bur D, Chucholowski A. Dehmlow H, Kitas EA, Obst U, Wessel HP. Preparation of pyrrolidinethiols and analogs as metalloprotease inhibitors. PCT Int Appl. 2002;160:WO0208185AI.
9. Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, Theuer J, Breu V, Mackman N, Luther T, Schneider W. Gulba D, Ganten D, Haller H, Luft FC. Angiotensin II (AT[1]) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol. 2000;157:111-122.
10. Muller DN, Heissmeyer V, Dechend R, Hampich F, Park JK, Fiebeler A, Shagdarsuren E, Theuer J, Elger M, Pilz B, Breu V, Schroer K, Ganten D, Dietz R, Haller H, Scheidereit C, Luft FC. Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB J. 2001;15:1822-1824.
11. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3methylglutaryl coenzyme a reductase inhibitor. Circulation. 2001; 104:576-581.
12. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappa-B activation in angiotensin II-induced cardiac injury. Hypertension. 2001;37:787-793.
13. Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Loffler BM. Human endothelin-converting enzyme (ECE-1): Three isoforms with distinct subcellular localizations. Biochem J. 1997;328:871-877.
14. Carvahlo KM, Boileau G, Cannargo ACM, Juliano L. A highly selective assay for neutral endopeptidase based on the cleavage of a fluorogenic substrate related to leu-enkephalin. Anal Biochem. 1998; 237:167-173.
15. Carmel A, Ehrlich-Rogozinsky S, Yaron A. A fluorimetric assay for angiotensin-I converting enzyme in human serum. Clin Chim Acta. 1979;93:215-220.
16. Mervaala EMA, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo, Muller DN, Fiebeler A, Ganten U, Ganten D, Luft FC. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension. 2001;37: 414-418.
17. Muller DN, Dechend R, Mervaala EMA, Schmidt F, Park J-K, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. Inhibition of NF-κB protects against end-organ damage in rats with human renin and angiotensinogen genes. Hypertension. 2000;35:193-201.
18. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, Maccherini M, Modesti PA. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res. 2001;88:961-968.
19. Schiffrin EL. Role of endothelin-I in hypertension and vascular disease. Am J Hypertens. 2001;14:83S-89S.
20. Pollock DM, Derebail VK, Yamamoto T, Pollock JS. Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats. Gen Pharmacol. 2000;34: 337-342.
21. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension. 2001; 37:781-786.
22. Park JB, Schiffrin EL. Et(a) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001;37:1444-1449.
23. Benigni A, Perico N, Remuzzi G. Endothelin antagonists and renal protection. J Cardiovasc Pharmacol. 2000;35(suppl 2):S75-S78.
24. Spieker LE, Noll G, Ruschitzka FT, Lüscher TF. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future? J Am Coll Cardiol. 2001;37:1493-1505.
25. Cao Z, Cooper ME, Wu LL, Cox AJ, Jandeleit-Dahm K, Kelly DJ, Gilbert RE. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension. 2000;36:561-568.